Oral Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder
Danial Khajavi(Roozbeh Hospital), Shahin Akhondzadeh(Arak University of Medical Sciences), Seyed-Hesammedin Abbasi, Mehdi Farokhnia(National Institutes of Health), Mandana Ashrafi(Roozbeh Hospital), Mina Tabrizi(Tehran University of Medical Sciences), Amirhossein Modabbernia(Icahn School of Medicine at Mount Sinai)
Cited by 87
Related Papers
Environmental risk factors for autism: an evidence-based review of systematic reviews and meta-analyses
|Molecular Autism|2017|793
The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
|JCI Insight|2023|200
Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review
|Pharmacological Reviews|2022|155
N-Acetylcysteine as an Adjunct to Risperidone for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia
|Clinical Neuropharmacology|2013|154
Comparing the efficacy and safety of<i>Crocus sativus</i>L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial
|Human Psychopharmacology Clinical and Experimental|2014|151